A generic cancer drug is reportedly responsible for children with autism showing "drastic improvement," the New York Post ...

As scientists continue to investigate the roots of autism, a generic cancer drug might hold the key. Leucovorin is prescribed ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

2025年3月7日，阿斯利康（AstraZeneca）公司宣布，其开展的3期临床试验MATTERHORN已获得积极顶线结果。该试验旨在评估PD-L1抑制剂Imfinzi（durvalumab）与标准治疗FLOT（fluorouracil、leucov ...

▎药明康德内容团队编辑阿斯利康（AstraZeneca）公司今日宣布，3期临床试验MATTERHORN获得积极顶线结果。其重磅PD-L1抑制剂Imfinzi（durvalumab）与标准治疗FLOT（fluorouracil、leucovorin、o ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF ...

A new study found that children whose mothers took an essential vitamin early in pregnancy had significantly higher verbal ...

"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...

An off-label prescription drug has been shown to help some non-verbal children with autism discover the ability to speak. The drug, leucovorin, is a prescription vitamin that functions similarly ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Jordan Miller, Arizona State University (THE CONVERSATION) In just a few short weeks, ...

The theory behind leucovorin's use for autism postulates that some children have a blockage in the transport of folic acid into the brain that potentially contributes to neurological symptoms.